Whitening composition, whitening product and application thereof

Abstract

The invention provides a whitening composition. The whitening composition comprises the following components: (a) phenylethyl resorcinol; and (b) a component for improving the whitening effect of the component (a) wherein the component (b) consists of the following components: (b-1) at least one acetylated hyaluronic acid or a salt thereof; and (b-2) at least one hyaluronic acid or a salt thereof with a molecular weight of less than 50kDa, the mass ratio of the component (b) to the component (a) is 1: 1-35: 1, and the mass ratio of the (b-1) to the (b-2) is 1: 15-40: 1. According to the application, acetylated hyaluronic acid or salt thereof, hyaluronic acid with the molecular weight of 50kDa or below or salt thereof and phenethyl resorcinol are combined, so that the whitening effect of phenethyl resorcinol is remarkably improved.

Description

Technical Field

[0001] This application belongs to the field of cosmetic technology, specifically relating to a composition that enhances the whitening effect of phenylethyl resorcinol, and related products and uses thereof. Background Technology

[0003] Phenethyl resorcinol is a type of resorcinol. Due to its bisphenol structure, it can effectively improve skin tone. Although phenylethyl resorcinol has a good whitening effect, it can also cause skin irritation. To reduce irritation, its maximum dosage is usually 0.5%. Therefore, finding ways to enhance the whitening effect with limited dosage is of great significance for the application of phenylethyl resorcinol and broadens the possibilities for the development and application of whitening products. Summary of the Invention

[0004] This application unexpectedly discovered that acetylated hyaluronic acid or its salt, hyaluronic acid or its salt with a molecular weight of less than 50 kDa, and phenylethyl resorcinol, in a certain ratio, can significantly enhance the whitening effect of phenylethyl resorcinol, thus completing the present invention.

[0005] This application provides a skin whitening composition, its uses, and products.

[0006] Specifically, this application relates to the following aspects:

[0007] 1. A skin whitening composition comprising the following components in a physiologically acceptable medium:

[0008] (a) phenylethyl resorcinol; and

[0009] (b) consists of (b-1) and (b-2).

[0010] (b-1) is at least one acetylated hyaluronic acid or a salt thereof.

[0011] The (b-2) is at least one hyaluronic acid or its salt with a molecular weight of less than 50 kDa.

[0012] The mass ratio of (b) to (a) is 1:1 to 35:1.

[0013] The mass ratio of (b-1) to (b-2) is 1:15-40:1.

[0014] 2. The whitening composition according to claim 1, wherein the mass ratio of (b) to (a) is 1:1 to 30:1.

[0015] 3. The whitening composition according to item 1 or 2, wherein the mass ratio of (b-1) to (b-2) is 1:10-30:1.

[0016] 4. The whitening composition according to any one of items 1-3, wherein the molecular weight of (b-2) is 379 Da-50 kDa.

[0017] 5. A whitening product comprising the whitening composition described in any one of items 1-4.

[0018] 6. The whitening product according to claim 5, wherein the mass content of (a) in the whitening product is 0.001%-0.5%.

[0019] 7. Use of at least one acetylated hyaluronic acid or a salt thereof and at least one hyaluronic acid or a salt thereof with a molecular weight of less than 50 kDa in enhancing the whitening effect of phenylethyl resorcinol.

[0020] 8. The use according to item 7, wherein the mass ratio of the combination of the at least one acetylated hyaluronic acid or its salt and the at least one hyaluronic acid or its salt with a molecular weight of less than 50 kDa to the phenylethyl resorcinol is 1:1-35:1, preferably 1:1-30:1.

[0021] 9. The use according to item 7 or 8, wherein the mass ratio between the at least one acetylated sodium hyaluronate and the at least one hyaluronic acid or its salt having a molecular weight of less than 50 kDa is 1:15-40:1, preferably 1:10-30:1.

[0022] 10. The use according to item 7 or 8, wherein the at least one hyaluronic acid or salt thereof with a molecular weight of less than 50 kDa is selected from hyaluronic acid or salt thereof with a molecular weight of 379 Da to 50 kDa.

[0023] The beneficial effects of this application are:

[0024] This application significantly enhances the whitening effect of phenylethyl resorcinol by combining acetylated hyaluronic acid or its salt, hyaluronic acid or its salt with a molecular weight of less than 50 kDa, and phenylethyl resorcinol.

[0025] Furthermore, the combination provided in this application can achieve a whitening effect similar to that at higher dosages with low dosage and low irritation of phenylethyl resorcinol. Detailed Implementation

[0026] The present application is further illustrated below with reference to embodiments. It should be understood that the embodiments are only used to further illustrate and explain the present application and are not intended to limit the present application.

[0027] Unless otherwise defined, technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art. While similar or identical methods and materials may be applied in experimental or practical applications, materials and methods are described herein. In case of conflict, the definitions included herein shall prevail. Furthermore, materials, methods, and examples are for illustrative purposes only and are not intended to be limiting. The present application is further described below with reference to specific embodiments, but is not intended to limit the scope of the application.

[0028] This application provides a skin whitening composition comprising the following components in a physiologically acceptable medium: (a) phenylethyl resorcinol; and (b) a composition consisting of (b-1) and (b-2), wherein (b-1) is at least one acetylated hyaluronic acid or a salt thereof, and (b-2) is at least one hyaluronic acid or a salt thereof with a molecular weight of less than 50 kDa, the mass ratio of (b) to (a) is 1:1 to 35:1, and the mass ratio of (b-1) to (b-2) is 1:15 to 40:1.

[0029] Component (b-1) may be an acetylated hyaluronic acid or a salt thereof, or a combination of two or more acetylated hyaluronic acids or their salts.

[0030] In some embodiments, the molecular weight of (b-1) is 10-100 kDa, for example, it can be 10 kDa, 15 kDa, 20 kDa, 25 kDa, 30 kDa, 35 kDa, 40 kDa, 45 kDa, 50 kDa, 55 kDa, 60 kDa, 65 kDa, 70 kDa, 75 kDa, 80 kDa, 85 kDa, 90 kDa, 95 kDa, 100 kDa, and any value between these values.

[0031] In some embodiments, the molecular weight of (b-2) is less than 50 kDa, for example, it can be 50 kDa, 45 kDa, 40 kDa, 35 kDa, 30 kDa, 25 kDa, 20 kDa, 15 kDa, 10 kDa, 9 kDa, 8 kDa, 7 kDa, 6 kDa, 5 kDa, 4 kDa, 3 kDa, 2 kDa, 1 kDa, 500 Da, 379 Da, and any value between these values. (b-2) can be a single hyaluronic acid or a salt thereof with a molecular weight of less than 50 kDa, or a combination of two or more hyaluronic acids or their salts with a molecular weight of less than 50 kDa.

[0032] In some implementations, (b-2) has a molecular weight of 379 Da to 50 kDa.

[0033] The mass ratio of (b) to (a) is 1:1 to 35:1, that is, the mass ratio of the combination of (b-1) and (b-2) to (a) is 1:1 to 35:1. For example, it can be 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, and any value between these values.

[0034] In some implementations, the mass ratio of (b) to (a) is 1:1 to 30:1.

[0035] The mass ratio of (b-1) to (b-2) is 1:15-40:1, for example, it can be 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1. 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, 40:1, and any value between these.

[0036] In some implementations, the mass ratio of (b-1) to (b-2) is 1:10-30:1.

[0037] In some embodiments, the whitening composition comprises, in a physiologically acceptable medium, the following components: (a) phenylethyl resorcinol; and (b) a mixture of (b-1) and (b-2), wherein (b-1) is at least one acetylated hyaluronic acid or a salt thereof, and (b-2) is at least one hyaluronic acid or a salt thereof with a molecular weight of 379 Da to 50 kDa, wherein the mass ratio of (b) to (a) is 1:1 to 30:1, and the mass ratio of (b-1) to (b-2) is 1:10 to 30:1.

[0038] In some embodiments, the whitening composition comprises: (a) phenylethyl resorcinol; (b) a mixture of (b-1) and (b-2); and a physiologically acceptable medium, wherein (b-1) is at least one acetylated hyaluronic acid or a salt thereof, and (b-2) is at least one hyaluronic acid or a salt thereof with a molecular weight of less than 50 kDa, wherein the mass ratio of (b) to (a) is 1:1 to 35:1, and the mass ratio of (b-1) to (b-2) is 1:15 to 40:1.

[0039] In some embodiments, the whitening composition comprises: (a) phenylethyl resorcinol; (b) a mixture of (b-1) and (b-2); and a physiologically acceptable medium, wherein (b-1) is at least one acetylated hyaluronic acid or a salt thereof, and (b-2) is at least one hyaluronic acid or a salt thereof with a molecular weight of 379 Da to 50 kDa, wherein the mass ratio of (b) to (a) is 1:1 to 30:1, and the mass ratio of (b-1) to (b-2) is 1:10 to 30:1.

[0040] The physiologically acceptable medium is a medium used to carry (a) and (b) above, which may be used in different physical forms of the composition, including solvents, thickeners, pH adjusters, preservatives, fragrances, etc.

[0041] This application also provides a whitening product comprising any one of the above-described whitening compositions.

[0042] Those skilled in the art will understand that the whitening product may be supplemented with solvents, excipients or other active ingredients known in the art as needed.

[0043] In some embodiments, the mass content of (a) and (b) in the whitening product is not particularly limited, and those skilled in the art can adjust it according to actual needs.

[0044] Since (a) excessive dosage may cause irritation, in some preferred embodiments, (a) is present in the whitening product at a mass content of less than 0.5%, preferably 0.001%-0.5%, for example, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, and any value between these values.

[0045] This application significantly enhances the whitening effect of (a) by combining (a) and (b), achieving a similar whitening effect to higher dosages with lower dosages of (a), and reducing the irritation caused by excessive dosages of (a).

[0046] This application also provides the use of at least one acetylated hyaluronic acid or a salt thereof and at least one hyaluronic acid or a salt thereof with a molecular weight of less than 50 kDa in enhancing the whitening effect of phenylethyl resorcinol.

[0047] Furthermore, the specific molecular weight and mass ratio of acetylated hyaluronic acid or its salt, hyaluronic acid with a molecular weight of less than 50 kDa, and the mass ratio between at least one acetylated hyaluronic acid or its salt and at least one hyaluronic acid or its salt with a molecular weight of less than 50 kDa and phenylethyl resorcinol are as described above.

[0048] The composition of this application, by combining acetylated hyaluronic acid or its salt, hyaluronic acid or its salt with a molecular weight of less than 50 kDa, and phenylethyl resorcinol, can significantly enhance the whitening effect of phenylethyl resorcinol. Furthermore, the composition of this application can achieve a similar whitening effect to that at higher dosages with low dosage and low irritation of phenylethyl resorcinol.

[0049] Example

[0050] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0051] Unless otherwise specified, all materials and reagents used in the following examples are commercially available. Specifically, acetylated sodium hyaluronate was purchased from Bloomage Biotechnology Co., Ltd. (trade name: Hymagic). TM -AcHA acetylated sodium hyaluronate, molecular weight: 40kDa), sodium hyaluronate A was purchased from Bloomage Biotechnology Co., Ltd. (trade name: Hybloom). TM Low molecular weight sodium hyaluronate (HA-TLM 3-5S, molecular weight: 40kDa), sodium hyaluronate B was purchased from Bloomage Biotechnology Co., Ltd. (trade name: Hybloom). TM Low molecular weight sodium hyaluronate (HA-TLM 20-40, molecular weight: 400kDa), sodium hyaluronate C was purchased from Bloomage Biotechnology Co., Ltd. (trade name: Nano). Enzymatically digested oligomeric sodium hyaluronate (molecular weight: 6521 Da), phenylethyl resorcinol was purchased from (trade name: 377).

[0052] The compositions of the examples and comparative examples were prepared according to Table 1.

[0053] Table 1

[0054]

[0055]

[0056] Table 2

[0057]

[0058]

[0059] Test case

[0060] 1. Subject requirements and study conditions

[0061] Thirty healthy participants aged 20-60 years with no history of skin diseases or cosmetic allergies were selected on a voluntary basis. Before the test, participants were required to clean their backs and remain stable under the test conditions for at least 30 minutes. During the test, participants were prohibited from drinking water, eating, engaging in strenuous activity, or using other products of the same type. The test environment was set at a temperature of 20-22°C and a relative humidity (RH) of 50%. All participants' cooperation was voluntary.

[0062] The experimental groups were as follows: Examples 1-5 involved 6 subjects, with 5 areas selected from each subject's back for the experiment. Examples 6-8 and the control group involved 6 subjects, with 4 areas selected from each subject's back for the experiment. Comparative Examples 1-5 involved 6 subjects, with 5 areas selected from each subject's back for the experiment. Comparative Examples 6-10 involved 6 subjects, with 5 areas selected from each subject's back for the experiment. Comparative Examples 11-14 involved 6 subjects, with 4 areas selected from each subject's back for the experiment.

[0063] 2. Experimental Procedure

[0064] The test was conducted in accordance with the specific requirements of Chapter 8, Section 6 of the "Cosmetic Safety Technical Specifications" (2015 Edition) (Appendix 7 of Announcement No. 17 of the National Medical Products Administration in 2021), specifically the first method for testing the whitening and freckle-removing efficacy of cosmetics using an ultraviolet-induced human skin melanization model. The unexposed area on the back of the subject was selected as the test site, with each melanized test area being no less than 0.5 cm². 2 The erythema dose (MED) should be located within each smear area. Determine the minimum erythema dose at the test site for the subject. Irradiate the same irradiation site once daily at a dose of 0.75 times the MED for 4 consecutive days using a sunlight simulator. The skin will undergo a melanization period of 4 days after irradiation, during which no treatment will be performed. On the 5th day after irradiation, apply the corresponding test substance (the composition of the above examples and comparative examples) to each test area. Apply the test substance continuously for 4 weeks according to the product instructions. Measure the ITA° value of the test area using a skin colorimeter in the 4th week. Calculate the rate of change using the following formula:

[0065] Improvement rate of ITA° value before and after use in each group = (ITA° value before use - ITA° value after use) / ITA° value before use

[0066] 3. Results

[0067] The results are shown in Table 3. The results show that all of Examples 1-8 can significantly improve the skin ITA° value and have a synergistic whitening effect.

[0068] The t-test was used for comparisons between groups. ns indicates no statistically significant difference; * indicates a p-value less than 0.05, indicating a statistically significant difference; ** indicates a p-value less than 0.01, indicating a highly statistically significant difference; *** indicates a p-value less than 0.001, indicating an extremely highly statistically significant difference.

[0069] Table 3

[0070]

Claims

1. A skin whitening composition comprising the following components in a physiologically acceptable medium: (a) phenylethyl resorcinol; and (b) consists of (b-1) and (b-2). (b-1) is at least one acetylated hyaluronic acid or a salt thereof. The (b-2) is at least one hyaluronic acid or its salt with a molecular weight of less than 50 kDa. The mass ratio of (b) to (a) is 1:1 to 35:

1. The mass ratio of (b-1) to (b-2) is 1:15-40:

1.

2. The whitening composition according to claim 1, wherein, The mass ratio of (b) to (a) is 1:1 to 30:

1.

3. The whitening composition according to claim 1 or 2, wherein, The mass ratio of (b-1) to (b-2) is 1:10-30:

1.

4. The whitening composition according to any one of claims 1-3, wherein, The molecular weight of (b-2) is 379 Da-50 kDa.

5. A whitening product comprising the whitening composition according to any one of claims 1-4.

6. The whitening product according to claim 5, wherein, The content of (a) in the whitening product is 0.001%-0.5% by mass.

7. Use of at least one acetylated hyaluronic acid or a salt thereof and at least one hyaluronic acid or a salt thereof with a molecular weight of less than 50 kDa in enhancing the whitening effect of phenylethyl resorcinol.

8. The use according to claim 7, wherein, The mass ratio of the combination of at least one acetylated hyaluronic acid or its salt and at least one hyaluronic acid or its salt with a molecular weight of less than 50 kDa to the phenylethyl resorcinol is 1:1-35:1, preferably 1:1-30:

1.

9. The use according to claim 7 or 8, wherein, The mass ratio between the at least one acetylated sodium hyaluronate and the at least one hyaluronic acid or its salt with a molecular weight of less than 50 kDa is 1:15-40:1, preferably 1:10-30:

1.

10. The use according to claim 7 or 8, wherein, The at least one hyaluronic acid or its salt with a molecular weight of less than 50 kDa is selected from hyaluronic acid or its salt with a molecular weight of 379 Da to 50 kDa.

Images